Jennifer Postelnek

532 total citations
12 papers, 269 citations indexed

About

Jennifer Postelnek is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Jennifer Postelnek has authored 12 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Jennifer Postelnek's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Multiple Myeloma Research and Treatments (3 papers) and Chemokine receptors and signaling (3 papers). Jennifer Postelnek is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Multiple Myeloma Research and Treatments (3 papers) and Chemokine receptors and signaling (3 papers). Jennifer Postelnek collaborates with scholars based in United States, Germany and Australia. Jennifer Postelnek's co-authors include Robert Townsend, Dong‐Qing Hu, Julie A. DeMartino, Cheng Liao, John Woods, Jay S. Fine, Jun Zhang, Loran M. Killar, Daniel Kukral and Anne Lewin and has published in prestigious journals such as Blood, The Journal of Immunology and Cancer Research.

In The Last Decade

Jennifer Postelnek

12 papers receiving 257 citations

Peers

Countries citing papers authored by Jennifer Postelnek

Since Specialization

Citations

This map shows the geographic impact of Jennifer Postelnek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Postelnek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Postelnek more than expected).

Fields of papers citing papers by Jennifer Postelnek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Postelnek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Postelnek. The network helps show where Jennifer Postelnek may publish in the future.

Co-authorship network of co-authors of Jennifer Postelnek

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Postelnek. A scholar is included among the top collaborators of Jennifer Postelnek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Postelnek. Jennifer Postelnek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology 2022 ·Regular and Young Investigator Award Abstracts ·Sonia Dolfi, (unknown), (unknown), Paolo A. Ascierto, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, John Wojcik, Jennifer Postelnek, Yu Wang, (unknown), Kaushal Mishra, (unknown), (unknown), Hussein A. Tawbi, Charlie Garnett‐Benson	2
2	Fit-for-purpose protein biomarker assay validation strategies using hybrid immunocapture-liquid chromatography-tandem-mass spectrometry platform: Quantitative analysis of total soluble cluster of differentiation 73 2020 ·Analytica Chimica Acta ·Yue Zhao, Huidong Gu, Jennifer Postelnek, (unknown), Long Yuan, Yan J Zhang, Jianing Zeng	7
3	Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors 2018 ·Cancer Research ·Lillian L. Siu, Howard A. Burris, Dung T. Le, Antoine Hollebecque, Neeltje Steeghs, Jean‐Pierre Delord, John Hilton, Bryan C. Barnhart, Emanuela Sega, Kinjal Sanghavi, Anke Klippel, Cyrus V. Hedvat, (unknown), Mark Donovan, (unknown), Paul Basciano, Jennifer Postelnek, Yue Zhao, Raymond P. Perez, Richard D. Carvajal	54
4	Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab 2016 ·The AAPS Journal ·Jennifer Postelnek, Robert Neely, Michael Robbins, Carol Gleason, Jon E. Peterson, Steven P. Piccoli	5
5	Effects of Elotuzumab on Soluble SLAMF7 Levels in Multiple Myeloma 2015 ·Blood ·Jennifer Postelnek, James P. Sheridan, Steve Keller, Tatiana Pazina, Jennifer Sheng, Valerie Poulart, Michael Robbins	5
6	RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Daigen Xu, Yong Kim, Jennifer Postelnek, Minh Diem Vu, Dong‐Qing Hu, Cheng Liao, (unknown), Jonathan C. Hsu, Jun Zhang, Achal Pashine, (unknown), John Woods, (unknown), Alison O’Mahony, Timothy D. Owens, Yan Lou, Ronald J. Hill, Satwant K. Narula, Julie A. DeMartino, Jay S. Fine	105
7	Novel pyrrolidine heterocycles as CCR1 antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·J. Robert Merritt, (unknown), Vidyadhar M. Paradkar, (unknown), Ruiyan Liu, (unknown), (unknown), (unknown), Michael J. Ohlmeyer, Elizabeth Quadros, (unknown), Jennifer Postelnek, (unknown), Weiqing Chen, Earl F. Kimble, (unknown), (unknown), Hema Desai, Kenneth C. Appell, Maria L. Webb	8
8	A CCR2/CCR5-dual antagonist, BMS-A, offers a potential novel oral therapy for the treatment of autoimmune disease (92.6) 2009 ·The Journal of Immunology ·Qihong Zhao, Jian Pang, Kim W. McIntyre, (unknown), Robert Townsend, Jennifer Postelnek, (unknown), (unknown), Gregory D. Ford, Stacey Conarello, Jenny Xie, Paul Davies, Joel C. Barrish, James M. Trzăskos, Luisa Salter–Cid, Murray McKinnon, Sandhya Mandlekar, Percy Carter	2
9	Novel Pyrrolidine Ureas as C−C Chemokine Receptor 1 (CCR1) Antagonists 2009 ·Journal of Medicinal Chemistry ·J. Robert Merritt, Jinqi Liu, Elizabeth Quadros, (unknown), Ruiyan Liu, Rui Zhang, (unknown), Jennifer Postelnek, (unknown), Weiqing Chen, Earl F. Kimble, W. Lynn Rogers, (unknown), (unknown), Hema Desai, Shalini Bansal, George King, Michael J. Ohlmeyer, Kenneth C. Appell, Maria L. Webb	18
10	Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis 2005 ·Journal of Autoimmunity ·(unknown), Daniel Kukral, Jennifer Postelnek, Bala Krishnan, Loran M. Killar, Anne Lewin, Steven G. Nadler, Robert Townsend	37
11	Prophylactic administration of abatacept (CTLA4-Ig; BMS-188667) prevents disease induction and bone destruction in a rat model of collagen-induced arthritis 2005 ·Arthritis Research ·(unknown), Daniel Kukral, Jennifer Postelnek, Bala Krishnan, Loran M. Killar, Steven G. Nadler, Robert Townsend	6
12	A HIGHLY SELECTIVE INHIBITOR OF IκB KINASE, BMS-345541, AUGMENTS GRAFT SURVIVAL MEDIATED BY SUBOPTIMAL IMMUNOSUPPRESSION IN A MURINE MODEL OF CARDIAC GRAFT REJECTION 2004 ·Transplantation ·(unknown), Jennifer Postelnek, Vojkan Susulic, Kim W. McIntyre, David J. Shuster, Yuping Qiu, F. Christopher Zusi, James R. Burke	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact